The safety and efficacy of recombinant human Interferon alfa 2b, administered nasally to hemodialysis patients as a preventative measure to avoid covid-19, were confirmed in an article published by researchers at the Center for Medical-Surgical Research (Cimeq) and the Center for Genetic Engineering and Biotechnology (CIGB), in the Journal of Renal Endocrinology.